The Shift to Proactive Medicine: An Industrial and Clinical Analysis of Neko Health’s $700 Million Series C Round and Global ScaleUp

Nelson Advisors
41 minutes ago
12 min read

The global venture capital landscape in 2025 and 2026 has witnessed a pronounced polarization. While macroeconomic pressures have forced a sharp reset in capital intensity for early-stage health technology startups, later-stage funding has increasingly concentrated in a select group of heavily capitalised, vertically integrated platforms. This trend culminated in the announcement that Stockholm-based preventative diagnostics firm Neko Health raised $700 million in a Series C funding round.

Co-founded in 2018 by Spotify’s Executive Chairman Daniel Ek and systems-oriented entrepreneur Hjalmar Nilsonne, Neko Health operates at the intersection of advanced multi-sensor hardware, artificial intelligence, and proactive primary care.

The massive capital injection arrives ahead of the launch of Neko Health’s first physical clinical location in the United States, positioning the company to disrupt the lucrative but highly competitive American longevity and preventative health market.

Macroeconomic Context and Venture Capital Inflection

Neko Health’s capitalisation trajectory reflects a dramatic progression of valuation and investor conviction. After operating in stealth mode for several years, initially supported by a €30Mmillion personal commitment from Daniel Ek through his investment vehicle Prima Materia, the company publicly launched in February 2023. The financial magnitude of the $700 Million Series C round is particularly striking when analysed against the broader preventative health screening venture market, which experienced a severe contraction in early 2026.

During the first half of 2026, total sector funding plummeted by roughly 75% compared to the same period in 2025, falling to just $118.85 Million. This drop was driven by the near-total disappearance of Series B and Series C rounds across the industry, with investors rotating toward smaller, early-stage exploratory financings with an average round size of just $8.49 Million.

Neko Health’s ability to secure $700 million under these contractionary conditions underscores a pronounced "winner-take-all" dynamic. Investors are showing a clear preference for vertically integrated operators that own their physical clinical footprint, hardware IP and patient relationship, rather than pure-play software or diagnostic algorithms.

Funding Round	Closed Date	Capital Raised	Post-Money Valuation	Lead Investors	Participating Investors
Series A	July 2023	€60 Million ($65 Million)	~€300 Million	Lakestar	Atomico, General Catalyst, Prima Materia
Series B	January 2025	$260 Million (€251.8 Million)	$1.8 Billion	Lightspeed Venture Partners	General Catalyst, O.G. Venture Partners, Rosello, Lakestar, Atomico
Series C	July 2026	$700 Million	$1.6B – $2.0B (Expected range)	Lightspeed Venture Partners, O.G. Venture Partners	Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, BDT & MSD

Furthermore, Neko Health’s financial performance demonstrates rapid operational scaling. At the time of its Series B round in January 2025, Neko Health was valued at $1.8 Billion. This valuation was highly speculative, representing roughly 666 times its trailing twelve-month (TTM) revenue of approximately $2.7 Million, calculated from 7,300 scans at roughly $370 each.

However, by September 2025, the company had scaled its annualised recurring revenue (ARR) to $21.9 Million, driven by the rollout of its London and Manchester clinics and high customer retention, with 80% of members pre-paying for their next annual scan. By the time of the Series C round, Neko Health had grown its active base to 100,000 members and achieved profitability at the clinic level, validating the platform's unit economics and laying the groundwork for the Series C injection.

Clinical and Corporate Architecture: Genesis and Vision

Hjalmar Nilsonne, who serves as CEO, brings a systems-engineering and machine-learning background to healthcare. Raised in a family of physicians, Nilsonne spent the early part of his career applying data-disaggregation algorithms to residential energy systems. In 2013, he founded Watty, a smart-home energy-analytics company that used machine learning and smart electricity meter data to disaggregate a home's power signal into individual appliance cycles to improve energy efficiency.

After Watty was acquired by Discovergy and Assa Abloy, Nilsonne translated this "data disaggregation" philosophy to human biology. He approached the human body not as an unpredictable system, but as a complex machine that continuously emits detectable physical signals before presenting clinical symptoms.

Just as machine learning could disaggregate a single high-frequency household electricity signal, Neko’s software disaggregates millions of multi-sensor physiological data points into specific organ system and cellular health trends.

Daniel Ek, who serves as Neko’s Chairman and principal financial backer, spent over a decade restructuring the global music industry through Spotify’s streaming and subscription algorithms. His involvement with Neko Health is part of a broader pledge to commit €1 billion of his personal wealth to European deep-tech "moonshots," which also includes his backing of defense AI firm Helsing. On September 30, 2025, Ek announced he would step down as CEO of Spotify at the end of the year to remain as Executive Chairman, focusing on capital allocation, long-term strategy, and regulatory efforts. This transition was designed to free up his operational capacity, allowing him to focus on capital allocation and strategic leadership in highly capital-intensive, long-horizon moonshots like Neko Health and Helsing AI.

The corporate governance of Neko Health (operating legally under HJN Sverige AB) is highly concentrated. The founders intentionally avoided early-stage angel syndicates and highly dilutive venture rounds to protect their R&D timeline and maintain control over clinical protocols.

To support this massive operational footprint, Neko Health has assembled a sophisticated clinical leadership team. Over half of Neko’s 1,000-person global workforce consists of clinical staff, with doctors and nurse practitioners seeing a maximum of nine patients per day, in stark contrast to the 30+ appointments standard in modern primary care.

The clinical operations are overseen by Dr. Sunita Mishra, Chief Medical Officer, who previously served as CMO at Amazon Health, and Dr. Nikita Kanani MBE, Global Medical Director, who was formerly the National Medical Director for Primary Care at NHS England and led the UK's COVID-19 vaccination program.

Proprietary Hardware and Software Engineering: The Four-Device Suite

A primary structural differentiator for Neko Health is its decision to reject third-party clinical hardware, opting instead to design, engineer, and manufacture its multi-sensor diagnostic suite in-house at its Stockholm headquarters.

By vertically integrating its hardware and software, Neko Health circumvents the high capital expenditure typically associated with purchasing clinical imaging devices and shortens the feedback loop between clinical insights and hardware engineering.

The primary physical examination is completed in under ten minutes and utilises a suite of over 70 sensors to capture 50 Million health data points, generating approximately 15 gigabytes of structured clinical data per session.

This data collection is driven by four proprietary hardware devices: Derma, Spectrum, Echo, and Neko Lens. The skin assessment relies on the Derma-2 system, which secured regulatory clearance in the United States in mid-2026. This system utilises a telethermographic array and multi-directional optical cameras to take over 2,000 high-resolution, stereoscopic images of the patient's entire body.

The system is capable of resolving dermal changes as small as 0.2 millimetres, mapping every mole to a personal "skin library" and using computer vision to track morphological changes, irregular pigmentation, and thermal anomalies over time to identify melanoma and other skin abnormalities.

To assess peripheral arterial health and small-vessel circulation, Neko Health engineered the Spectrum device. By utilsing multi-wavelength light spectroscopy and high-precision laser vibrometry, the system measures arterial stiffness, pulse wave velocity, and capillary blood flow down to the smallest blood vessels, providing an early warning indicator for atherosclerosis and peripheral artery disease. This technology is currently being validated in a sub-study of the Swedish CardioPulmonarybioImage 2 Study (SCAPIS 2), mapping microvascular function.

Cardiovascular performance is evaluated via the Echo device, which combines a standardized 12-lead electrocardiogram (ECG) with a specialized acoustic and mechanical cardiac sensor. This system assesses the heart's electrical conduction system alongside its mechanical and valvular function.

In high-volume clinics, Neko Health employs trained echocardiographers to perform targeted transthoracic echocardiograms (TTEs), including Global Longitudinal Strain (GLS) evaluations, to identify silent structural abnormalities, dilated cardiomyopathy, and sub-clinical valvular lesions.

In June 2026, Neko Health rolled out its most significant software and hardware update, integrating radiation-free body composition metrics directly into its proprietary optical scanner. By utilising 3D depth-sensing and advanced body-mapping algorithms, Neko Health calculates visceral fat percentage and subcutaneous fat volume without exposing patients to the ionizing radiation of a CT scan or the high costs of a DEXA scan or MRI.

This biometric imaging is paired with a miniaturized, on-site microfluidic lab that processes venous blood samples in minutes. Clinicians receive a comprehensive metabolic panel, including long-term blood sugar ($HbA1c$), highly sensitive C-reactive protein ($hs\text{-}CRP$), and complete lipid profiles ($HDL$, $LDL$, and triglycerides), prior to the patient's consultation.

To transition from a static annual assessment to a continuous, longitudinal preventative care relationship, Neko Health launched a mobile app integrated with consumer wearables. The application utilizes APIs to ingest continuous biometric telemetry, including sleep stages, step counts, active heart rate, and heart rate variability (HRV) from devices like Oura rings and Whoop bands. Clinicians utilize this contextual day-to-day data during consultations to isolate transient spikes in clinical metrics from sustained, lifestyle-driven patterns.

Clinical Efficacy, Longitudinal Data and Systemic Critiques

As Neko Health scales globally, the clinical efficacy and systemic impact of its direct-to-consumer preventative model are subject to intense scrutiny from clinical researchers, public health authorities, and health economists.

To establish transparency, Neko Health has published clinical data summaries detailing the findings from its Stockholm clinics, tracking the clinical outcomes of asymptomatic individuals who underwent full-body scanning.

Clinical Metric / Outcome Parameter	Year One (2023 Cohort)	Year Two (2024 Cohort)
Total Scanned Population	2,707 Individuals	4,362 Individuals
First-Time vs. Follow-Up Scans	100% First-Time	2,885 First-Time / 1,477 Follow-Up
Good Health / No Referral Required	78.5% of cohort	80.0% of cohort
Life-Saving / Severe Interventions	1.0% of cohort	1.2% of cohort (54 cases)
Key Life-Saving Diagnoses	Malignant Melanoma, Aortic Aneurysms, Severe Stenosis	Malignant Melanoma (25), Silent Myocardial Ischemia, Leukemia (2)
Significant Chronic Conditions	6.6% of cohort	4.0% of cohort (174 cases)
Key Chronic Diagnoses	Atrial Fibrillation, Type 2 Diabetes, Hypertension	Hypertension, Aortic Valve Disease, Type 2 Diabetes (56)
Reversible / Pre-Clinical Findings	2.1% of cohort	1.2% of cohort (52 cases)
Pre-Clinical Categories	Prediabetes ($HbA1c$), Early Arterial Stiffness	Prediabetic Blood Sugar, Pre-cancerous Skin Changes
Cleared / Resolved Post-Follow-up	3.5% of cohort	4.9% of cohort (217 cases)

Neko Health’s longitudinal data indicates that for returning members who presented with severe or significant conditions in 2023, 77% had their conditions successfully managed, medically optimized, or brought under clinical control by their second annual scan. To validate its hardware’s diagnostic performance within peer-reviewed frameworks, Neko Health is sponsoring the DermaFlow clinical trial (ClinicalTrials.gov ID: NCT06989216).

Initiated in August 2023 with study record updates posted through May 2025, this investigation evaluates the feasibility of full-body multi-modal imaging as a diagnostic support tool in primary care. The trial is designed to assess the sensitivity and specificity of Neko’s stereoscopic photography and thermal mapping in detecting melanoma, non-melanoma skin cancers, peripheral arterial disease, Raynaud's phenomenon, and chronic dermatological conditions like eczema and psoriasis.

Despite promising diagnostic statistics, mainstream clinical experts raise several methodological and systemic concerns. Critics point out that Neko's published outcomes are not derived from randomised controlled trials (RCTs) with matched control groups.

The cohort is self-selected, consisting of affluent, health-conscious individuals who possess the financial means to pay £299 or $400 out-of-pocket. Consequently, these findings cannot be easily generalized to the broader public. Dr. Johansson, an expert on screening evaluation, has warned that without a controlled cohort, Neko's claims are impossible to prove, and patients risk being harmed through overdiagnosis and over treatment of clinically insignificant anomalies.

Additionally, processing millions of biometric data points in asymptomatic individuals inevitably yields incidental, clinically insignificant findings. While Neko attempts to mitigate false positives by offering free in-house clinical follow-ups (which resolved 4.9% of anomalies in 2024), there remains a pronounced risk that benign findings will lead to patient anxiety and invasive, potentially harmful diagnostic procedures like biopsies. Computer vision models trained on skin mapping are also historically susceptible to algorithmic bias, demonstrating lower sensitivity when detecting malignant lesions on darker skin tones, presenting a clinical risk in diverse metropolitan markets like New York and London.

Finally, while Neko's clinicians resolve the vast majority of findings internally, approximately 4% of scans generate referrals to outside general practitioners or specialists. In countries with universal healthcare, such as the United Kingdom, this structure has drawn criticism from NHS representatives. Critics argue that Neko effectively privatizes the high-margin, low-complexity screening process while offloading the costly, long-term therapeutic care and workup of minor anomalies onto an already overburdened public primary care infrastructure. This is not a theoretical danger: a 2023 survey found that 90% of responding UK general practitioners had patients visit them specifically to discuss the results of private screening tests.

US Regulatory Pathways and Competitive Landscape

The United States represents both the largest healthcare market globally and the most challenging regulatory environment for preventative imaging startups. Neko Health’s strategic expansion into New York City, scheduled for late 2026, is built on a careful regulatory approach and an aggressive pricing strategy designed to undercut entrenched American competitors.

Unlike some longevity clinics that operate in regulatory gray areas, Neko Health has pursued formal regulatory pathways. On May 20, 2026, the company secured FDA 510(k) clearance for its Derma-2 system (Submission Number K253911). The FDA categorized the device as a Class 1 telethermographic system for adjunctive clinical use under Product Code LHQ (Regulation Number 884.2980). This clearance allows Neko Health to legally market its full-body thermal and optical imaging systems as diagnostic support tools within the US.

To support its expansion, Neko Health began recruiting a US Regional Regulatory Affairs Lead in early 2026. This executive is tasked with building Neko's US regulatory function from the ground up, maintaining a live in-region Quality Management System (QMS), and legally holding the statutory roles of US Agent, Initial Importer, and Medical Device Distributor.

Upon entering the US, Neko Health will face established direct-to-consumer screening companies that utilize magnetic resonance imaging (MRI) and computed tomography (CT). Neko Health’s competitive edge relies on a lower pricing model and a fundamentally different clinical modality.

Feature / Metric	Neko Health	Prenuvo	Ezra / Function Health
Core Diagnostic Modality	Multi-sensor optical, thermal, laser circulation, ECG, and blood	Whole-Body Magnetic Resonance Imaging (MRI)	AI-assisted MRI paired with low-dose CT (lungs/heart)
Internal Organ Imaging	None (Does not scan brain, liver, kidneys, or internal soft tissue)	Full internal organ imaging (head-to-ankle soft tissue)	AI-enhanced imaging of up to 13 major internal organs
Scan / Assessment Time	60 Minutes (includes doctor consultation)	60 Minutes (imaging only)	20 to 50 Minutes (imaging only)
Blood Biomarker Panels	Included (Venous microfluidics processed on-site in minutes)	Not included in base (Requires $3,999 Enhanced tier)	Included (100+ biomarkers via Function's annual membership)
Regional Pricing (2026)	$500 Projected US / £299 UK / 2,750 SEK Sweden	$2,499 Base / $3,999Enhanced	$499–$899 Scan + $499/Yea rmembership
Target Turnaround Time	Immediate (Consultation and results on-site same-visit)	1 to 2 Weeks (Radiology report delivered digitally)	7 to 10 Days (Delivered via mobile app)

Neko’s strategic positioning relies on a high-throughput, low-margin model. By pricing its scan at approximately $500, Neko Health positions itself as an "affordable luxury" accessible to middle-class consumers, contrasting with Prenuvo’s high-end $2,499 price point. Furthermore, Neko’s integration of rapid on-site blood diagnostics and real-time clinician consultations provides immediate feedback, eliminating the anxious one-to-two-week waiting period typical of traditional MRI screeners.

However, Neko Health’s model faces a clinical limitation: it does not provide deep internal soft-tissue imaging, meaning it cannot detect early-stage brain tumours, renal carcinomas, or spinal lesions, which remain the primary selling points of MRI-based platforms like Prenuvo and Ezra.

While the $700 Million Series C provides Neko Health with a massive capital runway, the company's long-term sustainability will depend on its ability to move beyond out-of-pocket consumer billing. CEO Hjalmar Nilsonne has stated that Neko’s ultimate goal is to leverage its accumulated longitudinal dataset to secure commercial partnerships with major health insurance providers. By proving that early, technology-driven screening reduces the incidence of late-stage cardiovascular events and metastatic skin cancers, Neko Health aims to position its diagnostic scan as a reimbursed primary care utility.

Financial analysts and venture capital funds speculate that Neko Health is aiming for a public market debut (IPO) by 2027 or 2028. This timeline is highly contingent on the commercial success of its New York City launch and its ability to maintain high margins as it scales a labour-intensive clinical footprint.

By keeping more than half of its 1,000-person global workforce in clinical roles, such as specialised doctors and nurse practitioners who review results directly with patients, Neko is building a trusted clinical brand, but must continuously leverage AI automation to prevent rising operational costs from limiting its scale.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech